KCPG
TEVA icon

Kavar Capital Partners Group’s Teva Pharmaceuticals TEVA Stock Holding History

Kavar Capital Partners Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,746
Closed -$35K – 416
2019
Q2 		$35K Buy
+3,746
New +$45.2K 0.01% 264
2018
Q3 		– Sell
-3,468
Closed -$84K – 347
2018
Q2 		$84K Hold
3,468
– – 0.04% 150
2018
Q1 		$59K Buy
+3,468
New +$67.7K 0.03% 173
2017
Q3 		– Sell
-30,072
Closed -$999K – 113
2017
Q2 		$999K Sell
30,072
-1,256
-4% -$38.9K 0.54% 67
2017
Q1 		$1M Buy
31,328
+1,112
+4% +$37.9K 0.56% 67
2016
Q4 		$1.09M Sell
30,216
-13,472
-31% -$538K 0.69% 61
2016
Q3 		$2.01M Buy
43,688
+1,110
+3% +$57.9K 1.3% 28
2016
Q2 		$2.14M Buy
42,578
+3,405
+9% +$181K 1.38% 25
2016
Q1 		$2.1M Buy
39,173
+4,507
+13% +$264K 1.39% 22
2015
Q4 		$2.27M Buy
34,666
+4,657
+16% +$288K 1.46% 17
2015
Q3 		$1.69M Buy
30,009
+695
+2% +$45.1K 1.2% 30
2015
Q2 		$1.73M Buy
29,314
+4,693
+19% +$290K 1.18% 32
2015
Q1 		$1.53M Buy
24,621
+2,037
+9% +$118K 1.3% 30
2014
Q4 		$1.3M Sell
22,584
-400
-2% -$22.3K 1.02% 42
2014
Q3 		$1.24M Sell
22,984
-1,125
-5% -$59.6K 1.06% 34
2014
Q2 		$1.26M Hold
24,109
– – 1.07% 27
2014
Q1 		$1.27M Buy
24,109
+91
+0.4% +$4.21K 1.05% 23
2013
Q4 		$962K Buy
+24,018
New +$946K 0.86% 47

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Kavar Capital Partners Group's TEVA Position: Q3 2019 in Review

Kavar Capital Partners Group sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 3,746 shares — an estimated $35K sold.

Kavar Capital Partners Group first reported a position in TEVA in Q4 2013 and held it in 18 quarters. The position peaked at $2.27M in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Kavar Capital Partners Group reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Kavar Capital Partners Group sold 3,746 Teva Pharmaceuticals shares in Q3 2019, an estimated $35K.
  • Kavar Capital Partners Group first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 18 quarters.
  • Kavar Capital Partners Group's Teva Pharmaceuticals position peaked at $2.27M in Q4 2015.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Kavar Capital Partners Group's 13F filing for Q3 2019, filed 12 Nov 2019.